JP6949027B2 - ジカウイルスワクチン - Google Patents

ジカウイルスワクチン Download PDF

Info

Publication number
JP6949027B2
JP6949027B2 JP2018532747A JP2018532747A JP6949027B2 JP 6949027 B2 JP6949027 B2 JP 6949027B2 JP 2018532747 A JP2018532747 A JP 2018532747A JP 2018532747 A JP2018532747 A JP 2018532747A JP 6949027 B2 JP6949027 B2 JP 6949027B2
Authority
JP
Japan
Prior art keywords
zika virus
virus
seq
zika
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018532747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504030A (ja
JP2019504030A5 (https=
Inventor
バルベロ カルザド ジャナ
バルベロ カルザド ジャナ
ネベンフフル マリオ
ネベンフフル マリオ
スクフルエグル ロバート
スクフルエグル ロバート
ウェーバー マイケル
ウェーバー マイケル
ウルッス ジュルゲン
ウルッス ジュルゲン
Original Assignee
バルネバ オーストリア ジーエムビーエイチ
バルネバ オーストリア ジーエムビーエイチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57821924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6949027(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by バルネバ オーストリア ジーエムビーエイチ, バルネバ オーストリア ジーエムビーエイチ filed Critical バルネバ オーストリア ジーエムビーエイチ
Publication of JP2019504030A publication Critical patent/JP2019504030A/ja
Publication of JP2019504030A5 publication Critical patent/JP2019504030A5/ja
Application granted granted Critical
Publication of JP6949027B2 publication Critical patent/JP6949027B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018532747A 2015-12-23 2016-12-23 ジカウイルスワクチン Active JP6949027B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP15202585 2015-12-23
EP15202585.4 2015-12-23
EP16161068.8 2016-03-18
EP16161068 2016-03-18
EP16176025 2016-06-23
EP16176049.1 2016-06-23
EP16176049 2016-06-23
EP16176025.1 2016-06-23
EP16182845 2016-08-04
EP16182845.4 2016-08-04
PCT/EP2016/082664 WO2017109225A1 (en) 2015-12-23 2016-12-23 Zika virus vaccine

Publications (3)

Publication Number Publication Date
JP2019504030A JP2019504030A (ja) 2019-02-14
JP2019504030A5 JP2019504030A5 (https=) 2019-12-26
JP6949027B2 true JP6949027B2 (ja) 2021-10-20

Family

ID=57821924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532747A Active JP6949027B2 (ja) 2015-12-23 2016-12-23 ジカウイルスワクチン

Country Status (19)

Country Link
US (14) US11331382B2 (https=)
EP (9) EP3393508B9 (https=)
JP (1) JP6949027B2 (https=)
KR (1) KR102950500B1 (https=)
CN (2) CN108697785B (https=)
AU (1) AU2016375338B2 (https=)
BR (1) BR112018012873A2 (https=)
CA (1) CA3009278A1 (https=)
DK (1) DK3393510T5 (https=)
ES (4) ES2973267T3 (https=)
FI (1) FI3393510T3 (https=)
HR (1) HRP20230273T1 (https=)
HU (1) HUE061679T2 (https=)
LT (1) LT3393510T (https=)
MX (1) MX2018007627A (https=)
PL (1) PL3393510T3 (https=)
SG (1) SG11201805120YA (https=)
SI (1) SI3393510T1 (https=)
WO (6) WO2017109224A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
EP3322441A4 (en) * 2015-07-16 2018-12-19 Bharat Biotech International Limited Vaccine compositions
ES2973267T3 (es) 2015-12-23 2024-06-19 Valneva Se Purificación de virus
BR112018077540A2 (pt) * 2016-07-08 2019-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
JP7301811B2 (ja) 2017-09-21 2023-07-03 ヴァルネヴァ エスイー 免疫原性チクングニアウイルスｃｈｉｋｖ－ｄｅｌｔａ ５ｎｓｐ３を含む医薬組成物を製造する方法
KR20200117981A (ko) 2017-11-03 2020-10-14 다케다 백신즈 인코포레이티드 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들
CN107988239B (zh) * 2017-11-29 2021-03-19 南方医科大学 一种寨卡病毒的重组基因及其制备方法和应用
MX2020005554A (es) * 2017-11-30 2020-10-12 Takeda Vaccines Inc Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
CN107904215B (zh) * 2017-12-27 2021-07-27 华农（肇庆）生物产业技术研究院有限公司 一种禽流感病毒的全悬浮培养方法
TWI658848B (zh) * 2018-02-13 2019-05-11 National Tsing Hua University 茲卡病毒疫苗組合物及其應用
CN110156880B (zh) * 2018-02-13 2022-12-16 吴夙钦 兹卡病毒疫苗组合物及其应用
CN119488586A (zh) * 2018-03-26 2025-02-21 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
CN108676780B (zh) * 2018-07-24 2021-08-10 华中农业大学 一种高效分离猪肠道冠状病毒的方法
CN109337876A (zh) * 2018-10-15 2019-02-15 北京世纪元亨动物防疫技术有限公司 一种猪流行性腹泻病毒的纯化方法
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
CN109627297B (zh) * 2018-12-29 2022-06-14 复旦大学 来自寨卡病毒e蛋白的中和表位及其应用
JP2022523044A (ja) * 2019-01-22 2022-04-21 ブルーバード バイオ， インコーポレイテッド ウイルスベクターを製造するための方法及びシステム
BR112021019845A2 (pt) * 2019-05-08 2022-02-15 Takeda Vaccines Inc Composições de vírus inativado e formulações de vacina contra zika
AU2020327602A1 (en) 2019-08-09 2022-01-27 Valneva Se Chikungunya vaccine formulations
EP4010016A1 (en) 2019-08-09 2022-06-15 Valneva SE Single shot chikungunya virus vaccine
EP4028511A1 (en) * 2019-09-09 2022-07-20 Valneva Austria GmbH Inactivation process for viruses
KR102243295B1 (ko) * 2019-11-15 2021-04-23 강원대학교산학협력단 지카바이러스의 외피 단백질을 포함하는 재조합 백신 조성물
KR102365464B1 (ko) * 2019-12-24 2022-02-22 강원대학교산학협력단 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
US12521429B2 (en) 2020-02-05 2026-01-13 New York Blood Center, Inc. Zika virus immunogenic compositions
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
JP2023515908A (ja) 2020-03-01 2023-04-14 ヴァルネヴァ・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ＣｐＧアジュバント化ＳＡＲＳ－ＣｏＶ－２ウイルスワクチン
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
JP7759333B2 (ja) * 2020-03-03 2025-10-23 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ ジカウイルスポリペプチド
AU2021232062A1 (en) 2020-03-06 2022-09-29 Colorado State University Research Foundation Production of vaccines comprising inactivated SARS-CoV-2 viral particles
UY39159A (es) 2020-04-06 2021-10-29 Valneva Austria Gmbh VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
JP2023526493A (ja) 2020-05-20 2023-06-21 タケダ ワクチン，インコーポレイテッド ジカウイルス特異的抗体の検出方法
US20230204567A1 (en) 2020-05-20 2023-06-29 Takeda Vaccines, Inc. Method for determining the potency of antigens
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
EP4476329A1 (en) * 2022-02-09 2024-12-18 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2025099278A2 (en) * 2023-11-08 2025-05-15 Valneva Austria Gmbh Immunogenic zika virus compositions and uses thereof
WO2026052882A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Yellow fever virus (yfv) compositions and production thereof
WO2026052881A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Chikungunya virus vaccine multidose formulation and use thereof in outbreaks

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US86061A (en) * 1869-01-19 Improved horse-power
DK1025209T3 (da) * 1997-08-28 2007-06-25 Cheil Jedang Corp Et attenueret japansk encephalitis-virus tilpasset til Vero-celle og en japansk encephalitis-vaccine
AU774045B2 (en) * 1998-09-02 2004-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Dengue viruses that are replication defective in mosquitos for use as vaccines
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
WO2002074963A1 (en) * 2001-03-16 2002-09-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Dengue viruses that are replication defective in mosquitos for use as vaccines
WO2002089840A1 (en) * 2001-05-10 2002-11-14 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
EP1608402B1 (en) 2003-03-24 2010-10-20 Intercell AG Improved vaccines
CN101516395B (zh) * 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
WO2009048633A2 (en) 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
BRPI0910686A2 (pt) * 2008-04-21 2015-09-29 Tissue Regeneration Therapeutics Inc células perivasculares do cordão umbilical humano geneticamente modificadas para a profilaxia contra agentes biológicos e químicos ou para o tratamento dos mesmos.
EP2370455B1 (en) * 2008-11-26 2019-07-03 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus like particle compositions and methods of use
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
EP3269386B1 (en) 2011-12-06 2022-09-14 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US10086061B2 (en) 2015-03-11 2018-10-02 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
EP3322441A4 (en) 2015-07-16 2018-12-19 Bharat Biotech International Limited Vaccine compositions
ES2973267T3 (es) 2015-12-23 2024-06-19 Valneva Se Purificación de virus
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
JP7301811B2 (ja) 2017-09-21 2023-07-03 ヴァルネヴァ エスイー 免疫原性チクングニアウイルスｃｈｉｋｖ－ｄｅｌｔａ ５ｎｓｐ３を含む医薬組成物を製造する方法

Also Published As

Publication number Publication date
ES2973267T3 (es) 2024-06-19
US12214033B2 (en) 2025-02-04
EP3393509B1 (en) 2024-02-28
EP3393507B1 (en) 2024-02-07
EP4357355A2 (en) 2024-04-24
CN108697785B (zh) 2022-08-02
JP2019504030A (ja) 2019-02-14
US20200017555A9 (en) 2020-01-16
EP4393938A2 (en) 2024-07-03
MX2018007627A (es) 2019-02-14
EP3393509A1 (en) 2018-10-31
US10744194B2 (en) 2020-08-18
EP3393510B1 (en) 2023-02-22
SI3393510T1 (sl) 2023-04-28
WO2017109224A1 (en) 2017-06-29
US10639365B2 (en) 2020-05-05
HUE061679T2 (hu) 2023-08-28
AU2016375338B2 (en) 2021-11-04
EP4393938A3 (en) 2024-08-07
US11207397B2 (en) 2021-12-28
EP4357355A3 (en) 2024-09-25
US10537630B2 (en) 2020-01-21
CN115381934A (zh) 2022-11-25
FI3393510T3 (fi) 2023-03-22
US10660950B2 (en) 2020-05-26
US12102673B2 (en) 2024-10-01
EP4218807A3 (en) 2023-09-06
US12005111B2 (en) 2024-06-11
US11406700B2 (en) 2022-08-09
CA3009278A1 (en) 2017-06-29
EP3393506B1 (en) 2024-03-13
ES2950887T3 (es) 2023-10-16
WO2017109227A1 (en) 2017-06-29
BR112018012873A2 (pt) 2018-12-04
WO2017109225A1 (en) 2017-06-29
US11331382B2 (en) 2022-05-17
CN108697785A (zh) 2018-10-23
EP4218807A2 (en) 2023-08-02
EP3393507C0 (en) 2024-02-07
US20200197506A1 (en) 2020-06-25
US20200384099A1 (en) 2020-12-10
KR102950500B1 (ko) 2026-04-08
US20200368342A1 (en) 2020-11-26
US20240108712A1 (en) 2024-04-04
EP4253403A3 (en) 2023-12-27
EP3393507A1 (en) 2018-10-31
HRP20230273T1 (hr) 2023-04-28
EP3393508A1 (en) 2018-10-31
US11219681B2 (en) 2022-01-11
EP3393509C0 (en) 2024-02-28
EP3393506C0 (en) 2024-03-13
ES2941967T3 (es) 2023-05-29
WO2017109229A1 (en) 2017-06-29
US11951163B2 (en) 2024-04-09
LT3393510T (lt) 2023-03-27
EP3393506A1 (en) 2018-10-31
KR20180097558A (ko) 2018-08-31
US20180371027A1 (en) 2018-12-27
DK3393510T5 (da) 2024-09-30
DK3393510T3 (da) 2023-03-13
US20230226165A1 (en) 2023-07-20
EP3393508C0 (en) 2023-06-07
US11524064B2 (en) 2022-12-13
AU2016375338A1 (en) 2018-07-05
ES2976311T3 (es) 2024-07-29
WO2017109228A1 (en) 2017-06-29
WO2017109223A1 (en) 2017-06-29
EP4253403A2 (en) 2023-10-04
EP3393508B1 (en) 2023-06-07
EP3393508B9 (en) 2023-09-27
SG11201805120YA (en) 2018-07-30
PL3393510T3 (pl) 2023-06-26
US20180369359A1 (en) 2018-12-27
US20250018023A1 (en) 2025-01-16
US20180362937A1 (en) 2018-12-20
US20190008945A1 (en) 2019-01-10
US20230056142A1 (en) 2023-02-23
US20210093707A1 (en) 2021-04-01
EP3393510A1 (en) 2018-10-31
US20220273786A1 (en) 2022-09-01
US20180362936A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
JP6949027B2 (ja) ジカウイルスワクチン
TW202203967A (zh) 不活化ＳＡＲＳ—ＣｏＶ—２病毒疫苗
JP2023520521A (ja) 不活化ＳＡＲＳ－ＣｏＶ－２ウイルスワクチン
HK40098392A (en) Zika virus vaccine
HK40103263A (en) Virus purification
HK1261388B (en) Zika virus vaccine
HK1261388A1 (en) Zika virus vaccine
HK1261325A1 (en) Zika virus purification
HK1261325B (en) Zika virus purification
HK1261326B (en) Virus purification
HK1261326A1 (en) Virus purification

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191107

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20191107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210921

R150 Certificate of patent or registration of utility model

Ref document number: 6949027

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250